
Opinion|Videos|March 10, 2025
Drug Delivery Systems in NMIBC
Author(s)Karim Chamie, MD, MSHS
An expert discusses how non–muscle invasive bladder cancer (NMIBC) treatment involves evolving delivery systems, transitioning from traditional systemic and intravesical approaches to advanced targeted technologies. Current research focuses on innovative platforms such as nanoparticle carriers, thermosensitive hydrogels, and personalized molecular delivery mechanisms to improve therapeutic efficacy and minimize systemic toxicity.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please provide a brief overview of delivery systems that are available to patients for treatment of NMIBC (ie, systemic IV delivery and bladder delivery systems).
- Discuss ongoing studies with investigational delivery systems in different subpopulations of NMIBC.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD
2
CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom
3
FDA grants breakthrough therapy, fast track designations to kidney cancer imaging agent
4
Mary Dunn, MSN, NP-C, OCN, RN, on advances reshaping advanced prostate cancer care
5






